Research programme: long-acting alpha interferon - Bolder BioTechnology

Drug Profile

Research programme: long-acting alpha interferon - Bolder BioTechnology

Alternative Names: BBT-012

Latest Information Update: 13 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bolder BioTechnology
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B; Hepatitis C

Most Recent Events

  • 13 Sep 2016 Preclinical development is ongoing for Hepatitis C and Hepatitis B in USA (Bolder BioTechnology pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top